Mayne Pharma Group Stock Performance
| MAYNF Stock | USD 3.10 0.10 3.33% |
On a scale of 0 to 100, Mayne Pharma holds a performance score of 4. The company secures a Beta (Market Risk) of 0.14, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Mayne Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Mayne Pharma is expected to be smaller as well. Please check Mayne Pharma's potential upside, daily balance of power, as well as the relationship between the Daily Balance Of Power and market facilitation index , to make a quick decision on whether Mayne Pharma's current price movements will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Mayne Pharma Group are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Mayne Pharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 98 M | |
| Total Cashflows From Investing Activities | -28.5 M |
Mayne |
Mayne Pharma Relative Risk vs. Return Landscape
If you would invest 276.00 in Mayne Pharma Group on September 13, 2024 and sell it today you would earn a total of 34.00 from holding Mayne Pharma Group or generate 12.32% return on investment over 90 days. Mayne Pharma Group is currently producing 0.2617% returns and takes up 4.246% volatility of returns over 90 trading days. Put another way, 37% of traded pink sheets are less volatile than Mayne, and 95% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Mayne Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mayne Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Mayne Pharma Group, and traders can use it to determine the average amount a Mayne Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0616
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MAYNF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.25 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Mayne Pharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mayne Pharma by adding it to a well-diversified portfolio.
Mayne Pharma Fundamentals Growth
Mayne Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Mayne Pharma, and Mayne Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mayne Pink Sheet performance.
| Return On Equity | -0.41 | |||
| Return On Asset | -0.0328 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.17) % | |||
| Current Valuation | 448.85 M | |||
| Shares Outstanding | 1.74 B | |||
| Price To Earning | 11.25 X | |||
| Price To Book | 0.73 X | |||
| Price To Sales | 0.65 X | |||
| Revenue | 423.92 M | |||
| EBITDA | (104.64 M) | |||
| Cash And Equivalents | 98.01 M | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 413.67 M | |||
| Debt To Equity | 0.74 % | |||
| Book Value Per Share | 0.32 X | |||
| Cash Flow From Operations | (7.21 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 1.29 B | |||
About Mayne Pharma Performance
By analyzing Mayne Pharma's fundamental ratios, stakeholders can gain valuable insights into Mayne Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mayne Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mayne Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia. Mayne Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange.Things to note about Mayne Pharma Group performance evaluation
Checking the ongoing alerts about Mayne Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Mayne Pharma Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mayne Pharma Group had very high historical volatility over the last 90 days | |
| Mayne Pharma Group has high likelihood to experience some financial distress in the next 2 years | |
| Mayne Pharma Group has accumulated 413.67 M in total debt with debt to equity ratio (D/E) of 0.74, which is about average as compared to similar companies. Mayne Pharma Group has a current ratio of 0.82, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Mayne Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mayne Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mayne Pharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mayne to invest in growth at high rates of return. When we think about Mayne Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 423.92 M. Net Loss for the year was (263.34 M) with profit before overhead, payroll, taxes, and interest of 171.03 M. | |
| Mayne Pharma Group has accumulated about 98.01 M in cash with (7.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 23.0% of Mayne Pharma outstanding shares are owned by corporate insiders |
- Analyzing Mayne Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mayne Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Mayne Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mayne Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mayne Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mayne Pharma's pink sheet. These opinions can provide insight into Mayne Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Mayne Pink Sheet analysis
When running Mayne Pharma's price analysis, check to measure Mayne Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mayne Pharma is operating at the current time. Most of Mayne Pharma's value examination focuses on studying past and present price action to predict the probability of Mayne Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mayne Pharma's price. Additionally, you may evaluate how the addition of Mayne Pharma to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| CEOs Directory Screen CEOs from public companies around the world |